在乳腺癌预防中进行机会窗试验以筛选有效药物并优化剂量。
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention.
作者信息
Aurilio G, Serrano D, Lazzeroni M, Guerrieri-Gonzaga A, Johansson H, Gandini S, Briata I M, D'Amico M, Spinaci S, Veronesi P, Galimberti V, Intra M, Heckman-Stoddard B M, Szabo E, Viale G, Bonanni B, DeCensi A
机构信息
Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, Milan, Italy.
Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
出版信息
NPJ Breast Cancer. 2025 Jun 9;11(1):53. doi: 10.1038/s41523-025-00745-8.
Window-of-opportunity trials are a path to screen effective agents and optimize dose in breast cancer risk reduction. We review the scientific evidence regarding the utility of window-of-opportunity trials to screen effective agents and optimize dose for successful risk reduction/interception of breast cancer. Low-dose tamoxifen was evaluated in a window-of-opportunity trial and then validated in a phase-III trial. We are now studying similar activity with low-dose exemestane.
机会窗试验是筛选有效药物并优化剂量以降低乳腺癌风险的一条途径。我们回顾了关于机会窗试验在筛选有效药物及优化剂量以成功降低/阻断乳腺癌风险方面效用的科学证据。低剂量他莫昔芬在一项机会窗试验中得到评估，随后在一项III期试验中得到验证。我们目前正在研究低剂量依西美坦的类似活性。
Zotero 插件